Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.53 |
| ▸ | TYMS | P04818 | 2/20 | 0.52 |
| ▸ | ENPP1 | P22413 | 2/20 | 0.50 |
| ▸ | P2RY1 | P47900 | 1/20 | 0.50 |
| ▸ | DTYMK | P23919 | 2/20 | 0.49 |
| ▸ | TRPM2 | O94759 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16871807 | 1.00 | POLB (0.53) | POLBTYMSENPP1P2RY1DTYMK | |
| SCHEMBL29941654 | 0.93 | POLB (0.54) | POLBTYMSENPP1P2RY1DTYMK | |
| SCHEMBL23679561 | 0.93 | POLB (0.49) | POLBTYMSENPP1P2RY1DTYMK | |
| SCHEMBL23679569 | 0.93 | POLB (0.49) | POLBTYMSENPP1P2RY1DTYMK | |
| SCHEMBL15794517 | 0.92 | DTYMK (0.55) | POLBENPP1P2RY1DTYMKTRPM2 | |
| Phosphoric Acid SCHEMBL16871802 | 0.87 | ADORA3 (0.50) | POLBENPP1P2RY1DTYMKTRPM2 | |
| SCHEMBL31685561 | 0.86 | TYMS (0.51) | TYMS | |
| SCHEMBL5982753 | 0.85 | ADORA3 (0.53) | — | |
| SCHEMBL5982748 | 0.85 | ADORA3 (0.53) | — | |
| SCHEMBL439797 | 0.85 | ADORA3 (0.53) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250289840-A1 | RNA STABILIZING SUBSTANCES AND METHODS OF USE | TEAM MEDICAL, LLC | 2025-09-18 | — | — | US | disclosed |
| EP-3130597-B1 | OLIGONUCLEOTIDE HAVING A NON-NATURAL NUCLEOTIDE AT THE 5'-TERMINAL | KYOWA KIRIN CO LTD (JP) | 2021-11-10 | — | — | EP | disclosed |
| EP-2891717-B1 | OLIGONUCLEOTIDE | KYOWA KIRIN CO LTD (JP) | 2020-04-29 | — | — | EP | disclosed |
| US-10378011-B2 | Oligonucleotide | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2019-08-13 | — | — | US | disclosed |
| US-10378011-B2 | Oligonucleotide | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2019-08-13 | — | — | US | disclosed |
| US-10342819-B2 | Oligonucleotide having non-natural nucleotide at 5′-terminal thereof | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2019-07-09 | — | — | US | disclosed |
| US-10342819-B2 | Oligonucleotide having non-natural nucleotide at 5′-terminal thereof | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2019-07-09 | — | — | US | disclosed |
| US-20170354673-A1 | OLIGONUCLEOTIDE HAVING NON-NATURAL NUCLEOTIDE AT 5'-TERMINAL THEREOF | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2017-12-14 | — | — | US | disclosed |
| US-20170354673-A1 | OLIGONUCLEOTIDE HAVING NON-NATURAL NUCLEOTIDE AT 5'-TERMINAL THEREOF | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2017-12-14 | — | — | US | disclosed |
| EP-3130597-A1 | OLIGONUCLEOTIDE HAVING NON-NATURAL NUCLEOTIDE AT 5'-TERMINAL THEREOF | Kyowa Hakko Kirin Co., Ltd. (JP) | 2017-02-15 | — | — | EP | disclosed |
| US-20150376611-A1 | OLIGONUCLEOTIDE | KYOWA KIRIN CO., LTD. (JP) | 2015-12-31 | — | — | US | disclosed |
| US-20150376611-A1 | OLIGONUCLEOTIDE | KYOWA KIRIN CO., LTD. (JP) | 2015-12-31 | — | — | US | disclosed |
| EP-2891717-A1 | OLIGONUCLEOTIDE | Kyowa Hakko Kirin Co., Ltd. (JP) | 2015-07-08 | — | — | EP | disclosed |
| US-5512486-A | Single step signal group-imidazole labeling of organic phosphate groups under aqueous conditions | NORTHEASTERN UNIVERSITY (US) | 1996-04-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10378011-B2 | Oligonucleotide | HNRNPA3, AGO2, RBM3 | POLB 785/4885TYMS 1779/4885ENPP1 1738/4885 |
| US-10342819-B2 | Oligonucleotide having non-natural nucleotide at 5′-terminal thereof | RNGTT, UPF1, NSUN3 | POLB 59/4885TYMS 139/4885ENPP1 1187/4885 |
| US-20250289840-A1 | RNA STABILIZING SUBSTANCES AND METHODS OF USE | SYNCRIP, SNRPA, RNASE1 | POLB 712/4885TYMS 3277/4885ENPP1 309/4885 |
| US-20170354673-A1 | OLIGONUCLEOTIDE HAVING NON-NATURAL NUCLEOTIDE AT 5'-TERMINAL THEREOF | RNGTT, UPF1, NSUN3 | POLB 60/4885TYMS 141/4885ENPP1 1203/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.